PDGF Agent May Offer Promise In Combination Therapy For CNV Secondary To AMD | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Wednesday, January 20, 2010

Email

Comments

Ocular surgery News

A novel platelet-derived growth factor currently being studied in clinical trials may boost the effect of anti-VEGF therapy and provide a benefit in patients with choroidal neovascularization secondary to age-related macular degeneration, according to a speaker here.

Retina Products and Equipment »

The most likely cause of the pigmentation depicted in this image is:
1. melanin
2. iron
3. silver
4. carbon
Check The Answer

CareCloud Central
CareCloud Central is a medical practice ... view product
OPMI LUMERA 700 Surgical Microscope
OPMI LUMERA 700 Incorporating the latest... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us